Comparison of risks generating overestimation or underestimation of Apparent permeability coefficient (Papp) and P-glycoproteain properties of dabigatran etexilate among four experimental settings
| Substrate | Detection | ±BNPP | AtoB (Dabigatran Etexilate Conc.) | BtoA (Dabigatran Etexilate Conc.) | Efflux Ratio | ||
|---|---|---|---|---|---|---|---|
| [14C]Dabigatran etexilate | LSC | − | Donor | Large overestimation | Donor | Correct | Incorrect |
| Receiver | Large overestimation | Receiver | Small overestimation | ||||
| [14C]Dabigatran etexilate | LSC | + | Donor | Small overestimation | Donor | Correct | Incorrect |
| Receiver | Moderate overestimation | Receiver | Correct | ||||
| Dabigatran etexilate | LC-MS/MS | − | Donor | Large reduction | Donor | Correct | Incorrect |
| Receiver | Correct | Receiver | Correct | ||||
| Dabigatran etexilate | LC-MS/MS | + | Donor | Correct | Donor | Correct | Correct |
| Receiver | Correct | Receiver | Correct | ||||
AtoB, apical to basa; BNPP, bis(p-nitrophenyl) phosphate; BtoA, basal to apical; CsA, cyclosporin A; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LSC, liquid scintillation counter.